ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Bibliographische Detailangaben
Hauptverfasser:	Morgensztern, D, Ong, TJ, Dols, MC, Aix, SP, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Vidal, OJ, Stewart, DJ, Fasola, G, Ardizoni, A, Weaver, J, Wolfsteiner, M, Talbot, D, Govindan, R
Format:	Conference item
Veröffentlicht:	Oxford University Press 2017

Ähnliche Einträge

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
von: Govindan, R, et al.
Veröffentlicht: (2017)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
von: Morgensztern, D, et al.
Veröffentlicht: (2018)

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
von: Talbot, D, et al.
Veröffentlicht: (2018)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
von: Daniel Morgensztern, et al.
Veröffentlicht: (2021-02-01)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
von: Morgensztern, D, et al.
Veröffentlicht: (2018)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
von: Ponce Aix, S, et al.
Veröffentlicht: (2020)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
von: Corey J. Langer, et al.
Veröffentlicht: (2018-07-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
von: Corey J. Langer, et al.
Veröffentlicht: (2021-01-01)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
von: Ajeet Gajra, et al.
Veröffentlicht: (2018-07-01)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
von: Hiraku Kokubu, et al.
Veröffentlicht: (2023-05-01)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
von: Julia Foldi, et al.
Veröffentlicht: (2021-02-01)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
von: Rui Wan, et al.
Veröffentlicht: (2023-06-01)

Macular Cystoid Edema Induced by Nab-Paclitaxel
von: Sara Alves Pereira, et al.
Veröffentlicht: (2022-04-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
von: Tomoyuki Araya, et al.
Veröffentlicht: (2020-12-01)

Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
von: Xi Guo, MD, et al.
Veröffentlicht: (2020-03-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
von: Kunihiko Funaishi, et al.
Veröffentlicht: (2017-06-01)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
von: Julia Foldi, et al.
Veröffentlicht: (2022-02-01)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
von: Harjinder Singh MD, et al.
Veröffentlicht: (2023-11-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
von: Zong Y, et al.
Veröffentlicht: (2020-12-01)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
von: Shuling Chen, et al.
Veröffentlicht: (2023-03-01)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
von: Thomas M, et al.
Veröffentlicht: (2017-10-01)

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer
von: Hiromi Okuyama, et al.
Veröffentlicht: (2018-10-01)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
von: Prakash Vishnu, et al.
Veröffentlicht: (2011-04-01)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
von: Vera eHirsh, et al.
Veröffentlicht: (2014-07-01)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
von: De Luca R, et al.
Veröffentlicht: (2018-06-01)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
von: Daniel J. Renouf, et al.
Veröffentlicht: (2022-08-01)

Bilateral macular edema secondary to nab-paclitaxel therapy for breast cancer
von: Zi-Yi Zhou, et al.
Veröffentlicht: (2024-10-01)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
von: Md Sazzad Hassan, et al.
Veröffentlicht: (2023-07-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
von: Annalisa Comandatore, et al.
Veröffentlicht: (2022-01-01)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
von: Jingjing Zhang, et al.
Veröffentlicht: (2023-03-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
von: Go Makimoto, et al.
Veröffentlicht: (2014-01-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
von: Frontiers in Oncology Editorial Office
Veröffentlicht: (2014-10-01)

Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
von: Yoshioka K, et al.
Veröffentlicht: (2022-03-01)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
von: Gridelli C, et al.
Veröffentlicht: (2018-05-01)

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study
von: Swapna Kochuveettil, et al.
Veröffentlicht: (2024-10-01)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
von: Ken Kamata, et al.
Veröffentlicht: (2023-09-01)

NAB engineering handbook /
von: 104 National Association of Broadcasters (United States), et al.

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
von: Elena Ferris Villanueva, et al.
Veröffentlicht: (2015-02-01)

Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report
von: Yu L, et al.
Veröffentlicht: (2024-04-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
von: Lukas M. Braun, et al.
Veröffentlicht: (2020-05-01)